RxDoctor Payments Data

Scott Brenner, DO

Psychiatry · Springfield, MONPI 1932471745

Payments from drug & device makers

$1,392in general payments, 2019–2025

Across 47 payments — averaging $29.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$393
  • Alkermes, Inc.$368
  • Otsuka America Pharmaceutical, Inc.$255
  • Neurocrine Biosciences, Inc.$223
  • Amgen$73
  • Hologic Sales And Service, LLC$20
  • plus $60 from 4 others

What the payments were for

  • Food & beverage$1,34497%
  • Education$483%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,392 in reported general payments places this provider in the 70th percentile of 680 psychiatry providers in Missouri.

See all psychiatry providers in Missouri

Medicare billing

Part B allowed, 2024
$4,887
Medicare patients
22
Services billed
55

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate35$124,882
ClozarilClozapine13$24,136
VraylarCariprazine Hcl12$19,887
BelsomraSuvorexant11$7,938
Paliperidone ErPaliperidone22$4,955
Lamotrigine ErLamotrigine18$3,025
Aripiprazole40$2,230
Divalproex Sodium ErDivalproex Sodium72$1,995
Buspirone Hcl96$1,767
Lurasidone Hcl12$1,579
Venlafaxine Hcl ErVenlafaxine Hcl110$1,172
Quetiapine Fumarate121$1,100
Duloxetine Hcl86$1,066
Olanzapine62$1,046
Hydroxyzine Hcl54$1,042

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$393$124,88235 claims
AbbVieVraylar$16$19,88712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 680 psychiatry providers in Missouri.

Other psychiatry in Springfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →